within Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A16A_OtherAlimentaryTractAndMetabolismProducts.A16AX18_Lumasiran;

model Lumasiran
  extends Pharmacolibrary.Drugs.ATC.A.A16AX18;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>A16AX18</td></tr><td>route:</td><td>subcutaneous</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Lumasiran is a small interfering RNA (siRNA) therapeutic indicated for the treatment of primary hyperoxaluria type 1 (PH1), a rare genetic disorder characterized by the overproduction of oxalate leading to kidney stones and renal failure. Approved by the FDA and EMA, it is administered subcutaneously and works by silencing the HAO1 gene to reduce hepatic glycolate oxidase production.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters based on healthy adult volunteers and patients with primary hyperoxaluria type 1 after subcutaneous administration.</p><h4>References</h4><ol><li><p>Michael, M, et al., &amp; Magen, D (2023). Lumasiran for Advanced Primary Hyperoxaluria Type 1: Phase 3 ILLUMINATE-C Trial. <i>American journal of kidney diseases : the official journal of the National Kidney Foundation</i> 81(2) 145–155.e1. DOI:<a href=&quot;https://doi.org/10.1053/j.ajkd.2022.05.012&quot;>10.1053/j.ajkd.2022.05.012</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35843439/&quot;>https://pubmed.ncbi.nlm.nih.gov/35843439</a></p></li><li><p>Jeon, JY, et al., &amp; Mitra, A (2022). Pharmacokinetic and Pharmacodynamic Modeling of siRNA Therapeutics - a Minireview. <i>Pharmaceutical research</i> 39(8) 1749–1759. DOI:<a href=&quot;https://doi.org/10.1007/s11095-022-03333-8&quot;>10.1007/s11095-022-03333-8</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35819583/&quot;>https://pubmed.ncbi.nlm.nih.gov/35819583</a></p></li><li><p>McDougall, R, et al., &amp; Wu, JT (2022). The Nonclinical Disposition and Pharmacokinetic/Pharmacodynamic Properties of . <i>Drug metabolism and disposition: the biological fate of chemicals</i> 50(6) 781–797. DOI:<a href=&quot;https://doi.org/10.1124/dmd.121.000428&quot;>10.1124/dmd.121.000428</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34154993/&quot;>https://pubmed.ncbi.nlm.nih.gov/34154993</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Lumasiran;
